Document Detail


Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
MedLine Citation:
PMID:  17163276     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: This subanalysis of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study in patients with essential hypertension assessed the relationship between the frequency of blood pressure self-measurement (BPSM) and the response to blood pressure (BP)-lowering therapy with olmesartan medoxomil, and the number of BP readings per week necessary to detect a mean systolic or diastolic BP reduction > or =5mm Hg.
METHODS: A total of 53 patients with essential hypertension received treatment with olmesartan medoxomil 10, 20 or 40 mg daily for 12 weeks. BPSM was performed for the first 9 weeks using a TensioPhone TP2 device. Patients were instructed to measure BP at least twice daily (morning and evening).
RESULTS: After the first 9 weeks of the 12-week treatment period, the extent of BP reduction correlated with the number of BPSMs. Systolic/diastolic BP reductions in patients with a 100% adherence to at least two BP measurements daily were -16.6/-8.0mm Hg compared with -0.2/-3.3mm Hg in patients with only a 75% adherence to at least one BP measurement daily. Obtaining five home BP readings per week resulted in a sensitivity of 94.8% and a specificity of 90.0% to detect a BP reduction of > or =5mm Hg.
CONCLUSION: Patients adhering to the instructions for BPSM (at least two measurements daily) had a better response to antihypertensive treatment with olmesartan medoxomil. Whether BPSM per se resulted in an improved adherence to therapy or whether the number of recordings was an indicator of already existing adherence remains to be determined. Obtaining at least five home BP readings per week was identified as the threshold for correctly predicting response to olmesartan medoxomil treatment.
Authors:
Silke Ewald; Johannes vor dem Esche; Sakir Uen; Fabian Neikes; Hans Vetter; Thomas Mengden
Related Documents :
2988326 - Effect of enalapril at rest, during tilt, static and dynamic exercise in systemic hyper...
3158296 - Hypotensive effect of plasma exchange in immune complex nephritis.
16053966 - Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambul...
20651156 - Vitamin d, blood pressure, and african americans: toward a unifying hypothesis.
21897296 - A novel technique for monitoring of fast variations in brain oxygen tension using an un...
556716 - Comparative pressure-length-diameter relationships of neonatal and adult rabbit ureters.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical drug investigation     Volume:  26     ISSN:  1173-2563     ISO Abbreviation:  Clin Drug Investig     Publication Date:  2006  
Date Detail:
Created Date:  2006-12-13     Completed Date:  2007-02-05     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  9504817     Medline TA:  Clin Drug Investig     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  439-46     Citation Subset:  IM    
Affiliation:
Sankyo Pharma GmbH, Munich, Germany. silke_ewald@sankyo-pharma.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / administration & dosage,  therapeutic use
Antihypertensive Agents / administration & dosage,  therapeutic use
Blood Pressure / drug effects*,  physiology
Blood Pressure Monitoring, Ambulatory / instrumentation*,  methods
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Hypertension / drug therapy*,  physiopathology
Imidazoles / administration & dosage,  therapeutic use*
Male
Middle Aged
Patient Compliance
Reproducibility of Results
Telemedicine / instrumentation,  methods
Tetrazoles / administration & dosage,  therapeutic use*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Imidazoles; 0/Tetrazoles; 6M97XTV3HD/olmesartan medoxomil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prophylaxis of postoperative nausea and vomiting in patients scheduled for breast surgery.
Next Document:  Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS...